

## Pharmacy Formulary Updates Effective April 1, 2021

The MVP Health Care® (MVP) Pharmacy & Therapeutics (P&T) Committee has determined that the following drugs, which have been recently approved by the FDA, will require prior authorization for at least the first six months following the date they are available on the market. The most current versions of our Formularies and Prior Authorization forms are available at [mvphealthcare.com](http://mvphealthcare.com).

### New Drugs (prior authorization required)

| Drug Name | Indication                                     | Commercial & Marketplace Tier | Medicare Part D Tier | MVP Medicaid  |
|-----------|--|-------------------------------|----------------------|---------------|
| Olinvyk   | Pain Management                                | Medical                       | Not Covered          | Medical       |
| Sutab     | Bowel Preparation for Colonoscopy              | Tier 3                        | Non-Formulary        | Non-Formulary |
| Oxlumo    | Primary Hyperoxaluria Type 1 (PH1)             | Tier 3                        | Non-Formulary        | Non-Formulary |
| Danyelza  | Relapsed or Refractory High-Risk Neuroblastoma | Medical                       | Not Covered          | Medical       |
| Orladeyo  | Hereditary Angioedema (HAE)                    | Tier 3                        | Tier 5               | Non-Formulary |
| Winlevi   | Acne Vulgaris                                  | Tier 3                        | Non-Formulary        | Non-Formulary |
| Qdolo     | Pain Management                                | Tier 3                        | Non-Formulary        | Non-Formulary |
| Eysuvis   | Dry Eye  | Tier 3                        | Non-Formulary        | Non-Formulary |
| Nyvepria  | Febrile Neutropenia                            | Tier 3                        | Non-Formulary        | Non-Formulary |

### Commercial & Exchange (non-Medicare)

| New generic formulary additions |                          |
|---------------------------------|--------------------------|
| Drug Name                       | Tier                     |
| nitazoxanide (Alinia)           | Tier 1 (Tier 2 Exchange) |
| ivermectin (Sklice)*            | Tier 1 (Tier 2 Exchange) |
| asenapine (Saphris)*            | Tier 1 (Tier 2 Exchange) |
| abiraterone 500mg (Zytiga)      | Tier 1 (Tier 2 Exchange) |

All brands will be non-formulary, Tier 3

\*Brand name Sklice and Saphris will be Tier 2 for Medicaid

### Miscellaneous Updates

#### COVID-19 Vaccines

Claims for COVID-19 vaccines are processing. Vaccines are covered by the federal government and the administration costs are covered by the plans.

#### Commercial and Exchange Business: February 2021 Changes

Breztri, Rhopressa and Orilissa will be added to Tier 2.

To view all communications, visit [mvphealthcare.com/FastFax](http://mvphealthcare.com/FastFax)

To receive future FastFax messages by email, contact your Professional Relations Representative

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

